Literature DB >> 23935556

Diagnosis, prognosis, and management of primary sclerosing cholangitis.

Cyriel Ponsioen1.   

Abstract

Entities:  

Year:  2013        PMID： 23935556      PMCID： PMC3736784     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.

Authors:  Kirsten Boonstra; Karel J van Erpecum; Karin M J van Nieuwkerk; Joost P H Drenth; Alexander C Poen; Ben J M Witteman; Hans A R E Tuynman; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

2.  Diagnosis and management of primary sclerosing cholangitis.

Authors:  Roger Chapman; Johan Fevery; Anthony Kalloo; David M Nagorney; Kirsten Muri Boberg; Benjamin Shneider; Gregory J Gores
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

3.  Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Kirsten Muri Boberg; Peter Jebsen; Ole Petter Clausen; Aksel Foss; Lars Aabakken; Erik Schrumpf
Journal:  J Hepatol       Date:  2006-06-21       Impact factor: 25.083

4.  The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.

Authors:  Cynthia Levy; James Lymp; Paul Angulo; Gregory J Gores; Nicholas Larusso; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

5.  Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

Authors:  Kirsten Boonstra; Rinse K Weersma; Karel J van Erpecum; Erik A Rauws; B W Marcel Spanier; Alexander C Poen; Karin M van Nieuwkerk; Joost P Drenth; Ben J Witteman; Hans A Tuynman; Anton H Naber; Paul J Kingma; Henk R van Buuren; Bart van Hoek; Frank P Vleggaar; Nan van Geloven; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Hepatology       Date:  2013-10-17       Impact factor: 17.425

6.  24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

Authors:  Peter Fickert; Martin Wagner; Hanns-Ulrich Marschall; Andrea Fuchsbichler; Gernot Zollner; Oleksiy Tsybrovskyy; Kurt Zatloukal; Jie Liu; Michael P Waalkes; Cathleen Cover; Helmut Denk; Alan F Hofmann; Hartmut Jaeschke; Michael Trauner
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682
  6 in total
  2 in total

Review 1.  Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review.

Authors:  Fatima Isa; Grace M Turner; Geetinder Kaur; Derek Kyte; Anita Slade; Tanya Pankhurst; Larissa Kerecuk; Thomas Keeley; James Ferguson; Melanie Calvert
Journal:  Health Qual Life Outcomes       Date:  2018-07-05       Impact factor: 3.186

2.  Patient and clinician opinions of patient reported outcome measures (PROMs) in the management of patients with rare diseases: a qualitative study.

Authors:  Olalekan Lee Aiyegbusi; Fatima Isa; Derek Kyte; Tanya Pankhurst; Larissa Kerecuk; James Ferguson; Graham Lipkin; Melanie Calvert
Journal:  Health Qual Life Outcomes       Date:  2020-06-10       Impact factor: 3.186
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.